Physician profile
Mia Singleton-Ben
NPI 1619040342
$632.05
in general payments reported to CMS, 2019-2025
17 companies · $75.02 in 2025
The $75.02 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $49.45 · 2021: $183 · 2022: $57.30 · 2023: $49.42 · 2024: $73.14 · 2025: $75.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $115.98 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $93.41 | 2021-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $76.11 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $68.40 | 2019-2021 | |
| Aytu Biopharma, INC. | $48.56 | 2020-2024 | Karbinal |
| Sanofi Pasteur INC. | $45.89 | 2019-2025 | |
| Seqirus USA INC | $37.54 | 2024-2025 | Flucelvax, Fluad |
| Sobi, INC | $24.99 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.94 | 2021 | |
| Millicent US INC | $14.83 | 2025 | Femlyv |
| Takeda Pharmaceuticals U.S.A., INC. | $14.59 | 2021 | |
| Genzyme Corporation | $14.13 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $13.73 | 2024 | Kristalose |
| Corium, LLC | $12.09 | 2022 | |
| Genentech USA, INC. | $12.09 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11.58 | 2021 | |
| Shire North American Group INC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mia Singleton-Ben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.